cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Zentalis Pharmaceuticals Inc
2 own
3 watching
Current Price
$3.98
$0.04
(1.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
291.18M
52-Week High
52-Week High
29.03000
52-Week Low
52-Week Low
3.27000
Average Volume
Average Volume
1.2M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization291.18M
icon52-Week High29.03000
icon52-Week Low3.27000
iconAverage Volume1.2M
iconDividend Yield--
iconP/E Ratio--
What does the Zentalis Pharmaceuticals Inc do?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company s other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Read More
How much money does Zentalis Pharmaceuticals Inc make?
News & Events about Zentalis Pharmaceuticals Inc.
ValueWalk
1 year ago
ZNTL stocks biggest holder just boosted its stake Shares of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) are cooling off a bit Thursday ... Read more ZNTL stocks biggest holder just boosted its stake Shares of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) are cooling off a bit Thursday after yesterdays...
Globe Newswire
1 year ago
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib Company also announces collaborations with Foundation Medicine and Roche ...
Globe Newswire
1 year ago
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy combination study, including data on CCNE1 amplification and / or Cyclin E1 expression, in the first...
Business Wire
1 year ago
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (Zentalis or the Company). The investigations concern whether certain of the Zentalis officers and directors breached their fiduciary duties to...
Globe Newswire
1 year ago
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders. The investigation concerns potential ...
Frequently Asked Questions
Frequently Asked Questions
What is Zentalis Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Zentalis Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Zentalis Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Zentalis Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Zentalis Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Zentalis Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Zentalis Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Zentalis Pharmaceuticals Inc?
plus_minus_icon
What percentage is Zentalis Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Zentalis Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.98
$0.04
(1.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00